Table 2 |
||||||
| Clinicopathological features of patients with AITL developing renal involvement | ||||||
| Author | Sex | Age | Type of renal lesion | Interval (months) | Treatment | Clinical outcome |
| Wood and Harkins [13] | M | 76 | Diffuse proliferative glomerulonephritis | 0 | Corticosteroid, cyclophosphamide | Dead for lymphoma |
| Wood and Harkins [13] | M | 79 | Minimal change disease | 0 | Dialysis | Dead for renal failure |
| Bhat et al [8] | F | 77 | Acute renal failure with Bence-Jones proteinuria | 4 | None | Dead for sepsis |
| Platzer et al [11] | M | 64 | Renal failure | 0 | Prednisolone | CR |
| Bello et al [15] | M | 61 | Fanconi syndrome | 0 | Hydrocortisone | CR |
| Bignon et al [23] | M | 70 | Dysproteinaemia | 0 | n.a. | n.a. |
| Yamazaki et al [26] | M | 72 | Endocapillary proliferative glomerulonephritis | 0 | Vincristine, prednisolone | Dead for alimentary tract bleeding |
| Nakamoto et al [10] | M | 40 | Acute interstitial nephritis | 16 | Prednisolone, cyclophosphamide | At 60-month follow-up, no signs of relapse |
| Duwaji et al [28] | M | 71 | Proliferative glomerulonephritis | 2 | CHOP regimen | Dead for sepsis |
| Lim et al [33] | M | 33 | Amyloidosis | 12 | CHOP regimen | At 12-month follow-up, no signs of relapse |
| Hamidou et al [12] | M | 56 | Vasculitis | 0 | CHOP regimen | Dead for renal failure |
| De Samblanx et al [2] | M | 67 | Proliferative glomerulonephritis | 0 | CHOP regimen | At 12-month follow-up, no signs of relapse |
| Goto et al [9] | M | 73 | Direct invasion by lymphoma | 0 | CHOP regimen | At 20-month follow-up, no signs of relapse |
| Miura et al [7] | M | 70 | IgM-λ glomerular thrombi | 2 | CHOP regimen | At 3-month follow-up, no signs of relapse |
| Tagashi et al [16] | M | 21 | Nephrotic syndrome | 0 | CHOP regimen | At 36-month follow-up, no signs of relapse |
CR complete remission; n.a. not available, CHOP Cyclophosphamide, doxorubicin, vincristine, prednisolone.
Ambrosio et al. Diagnostic Pathology 2012 7:50 doi:10.1186/1746-1596-7-50
